Bevacizumab
- Generic Name
- Bevacizumab
- Brand Names
- Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216974-75-3
- Unique Ingredient Identifier
- 2S9ZZM9Q9V
- Background
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...
- Indication
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...
- Associated Conditions
- Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Associated Therapies
- First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT06339424
- Locations
- 🇨🇳
Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 1048
- Registration Number
- NCT06336707
- Locations
- 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Shanghai, Shanghai, China
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 46
- Registration Number
- NCT06332079
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
- Conditions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT06329570
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 240
- Registration Number
- NCT06323382
- Locations
- 🇨🇳
Chinese PLA hospital, Beijing, Beijing, China
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
- Conditions
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT06313970
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Pardis Noor Medical Imaging and Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06311851
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Lebanese University
- Target Recruit Count
- 50
- Registration Number
- NCT06307249
- Locations
- 🇱🇧
Lebanese University, Tripoli, North Lebanon, Lebanon
🇱🇧Haykel Hospital, Tripoli, North Lebanon, Lebanon
A Study of Valemetostat Tosylate (DS-3201b) with Atezolizumab and Bevacizumab in HCC
- Conditions
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 45
- Registration Number
- NCT06294548
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 65
- Registration Number
- NCT06285019
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.